Future directions for the early detection of colorectal cancer recurrence

Journal of Cancer

Volumn 5, Issue 4, 2014, Pages 272-280

  Walker, Avery S ^a   Johnson, Eric K ^a   Maykel, Justin A ^b   Stojadinovic, Alex ^c   Nissan, Aviram ^d   Brucher, Bjorn ^e   Champagne, Bradley J ^f   Steele, Scott R ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e Virginia Health System   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

biomarkers; Colorectal cancer; recurrence

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL MEMBRANE PROTEIN; MICRORNA; MICRORNA 29C; PLASTIN 3; RETINOIC ACID INDUCED PROTEIN 3; TUMOR MARKER; UNCLASSIFIED DRUG;

AUTOFLUORESCENCE IMAGING; BAYES THEOREM; CANCER DIAGNOSIS; CANCER RECURRENCE; CHROMOENDOSCOPY; COLORECTAL CANCER; CONFOCAL LASER MICROSCOPY; EARLY DIAGNOSIS; ENDOSCOPY; GENE; METASTASIS ASSOCIATED IN COLON CANCER 1 GENE; MICROSATELLITE INSTABILITY; NOMOGRAM; OVERALL SURVIVAL; REVIEW;

EID: 84897007117     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8871     Document Type: Review

References (57)

1. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD. Practice parameters for the management of colon cancer. Dis Colon Rectum. Aug 2012;55(8):831-843.
2. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. Nov 2007;50(11):1783-1799.
3. Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between <=5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. Jul 2013;108(1):9-13.
4. Cortet M, Grimault A, Cheynel N, Lepage C, Bouvier A, Faivre J. Patterns of recurrence of obstructing colon cancers after surgery for cure: a population- based study. Colorectal Dis. May 2 2013.
5. Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg. Oct 2002;236(4):522-529; discussion 529-530.
6. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3:CD004078.
7. Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2010;(1):CD007046.
8. Stojadinovic A, Bilchik A, Smith D, et al. Clinical decision support and individualized prediction of survival in colon cancer: bayesian belief network model. Ann Surg Oncol. Jan 2013;20(1):161-174.
9. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. Feb 15 2001;19(4):980-991.
10. Adjuvant! Online Decision making tools for health care professionals. Accessed September 1, 2013.
11. MSKCC. Colorectal Cancer Nomogram: Post-Surgery. http://www.mskcc.org/mskcc/html/83364.cfm. Accessed 06 Aug, 2013.
12. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. Jan 20 2008;26(3):380-385.
13. Memorial Sloan-Kettering Cancer Center, Colorectoral Cancer Nomogram. http://nomograms.mskcc.org/Colorectal/index.aspx. Accessed September 1, 2013.
14. Stojadinovic A, Nissan A, Eberhardt J, Chua TC, Pelz JO, Esquivel J. Development of a Bayesian Belief Network Model for personalized prognostic risk assessment in colon carcinomatosis. Am Surg. Feb 2011;77(2):221-230.
15. Stojadinovic A, Peoples GE, Libutti SK, et al. Development of a clinical decision model for thyroid nodules. BMC Surg. 2009;9:12.
16. Aghili M, Izadi S, Madani H, Mortazavi H. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol. Mar 2010;6(1):35-41.
17. Avital I, Langan RC, Summers TA, et al. Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. J Cancer. 2013;4(3):172-192.
18. Bravo HC, Pihur V, McCall M, Irizarry RA, Leek JT. Gene expression anti- profiles as a basis for accurate universal cancer signatures. BMC Bioinformatics. 2012;13:272.
19. Fernandes LC, Kim SB, Saad SS, Matos D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol. 28 2006;12(24):3891-3894.
20. Anthony T, Simmang C, Hyman N, et al. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis Colon Rectum. Jun 2004;47(6):807-817.
21. Amri R, Bordeianou LG, Sylla P, Berger DL. Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J Surg Oncol. Jul 2013;108(1):14-18.
22. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338-351.
23. Makis W, Kurzencwyg D, Hickeson M. 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence. Clin Imaging. Aug 28 2013.
24. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. Nov 15 1998;58(22):5248-5257.
25. Han SW, Lee HJ, Bae JM, et al. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer. May 1 2013;132(9):2209-2216.
26. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 13 2000;342(2):69-77.
27. Tikidzhieva A, Benner A, Michel S, et al. Microsatellite instability and Beta2- Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer. Mar 13 2012;106(6):1239-1245.
28. Lin SP, Lee YT, Yang SH, et al. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett. 28 2013;328(2):226-234.
29. Garcia M, Choi C, Kim HR, et al. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology. Jul 2012;143(1):48-50 e41.
30. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med. 2009;1(4):36.
31. Shirahata A, Sakata M, Kitamura Y, et al. MACC 1 as a marker for peritoneal- disseminated gastric carcinoma. Anticancer Res. Sep 2010;30(9):3441-3444.
32. Stein U, Dahlmann M, Walther W. MACC1 - more than metastasis Facts and predictions about a novel gene. J Mol Med (Berl). 2010;88(1):11-18.
33. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. Jan 2009;15(1):59-67.
34. Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. Apr 2011;141(4):895-898.
35. Isella C, Mellano A, Galimi F, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg. Jun 2013;257(6):1089-1095.
36. Kawamura M, Saigusa S, Toiyama Y, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. Apr 2012;32(4):1527-1531.
37. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-273.
38. Delanote V, Vandekerckhove J, Gettemans J. Plastins: versatile modulators of actin organization in (patho)physiological cellular processes. Acta Pharmacol Sin. Jul 2005;26(7):769-779.
39. Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. Apr 1 2013;73(7):2059-2069.
40. Zougman A, Hutchins GG, Cairns DA, et al. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer. Jan 2013;49(2):531-539.
41. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. Aug 1 2008;68(15):6416-6424.
42. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. Aug 2010;42(8):1273-1281.
43. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. Feb 2012;36(1):e61-67.
44. Kuo TY, Hsi E, Yang IP, Tsai PC, Wang JY, Juo SH. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS One. 2012;7(2):e31587.
45. Yang IP, Tsai HL, Hou MF, et al. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis. Aug 2012;33(8):1522-1530.
46. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. Sep 1 2010;28(25):3937-3944.
47. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. Dec 10 2011;29(35):4611-4619.
48. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. May 10 2013;31(14):1775-1781.
49. Trivedi PJ, Braden B. Indications, stains and techniques in chromoendoscopy. QJM. Feb 2013;106(2):117-131.
50. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. Feb 2006;101(2):343-350.
51. dos Santos CE, Lima JC, Lopes CV, et al. Computerized virtual chromoendoscopy versus indigo carmine chromoendoscopy combined with magnification for diagnosis of small colorectal lesions: a randomized and prospective study. Eur J Gastroenterol Hepatol. Nov 2010;22(11):1364-1371.
52. Aminalai A, Rosch T, Aschenbeck J, et al. Live image processing does not increase adenoma detection rate during colonoscopy: a randomized comparison between FICE and conventional imaging (Berlin Colonoscopy Project 5, BECOP-5). Am J Gastroenterol. Nov 2010;105(11):2383-2388.
53. Curvers WL, van Vilsteren FG, Baak LC, et al. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc. Feb 2011;73(2):195-203.
54. Kuiper T, van den Broek FJ, Naber AH, et al. Endoscopic trimodal imaging detects colonic neoplasia as well as standard video endoscopy. Gastroenterology. Jun 2011;140(7):1887-1894.
55. [Internet] Fujiya M, Moriichi K, Ueno N, Saitoh Y, Kohgo Y. Autofluorescence Imaging for Diagnosing Intestinal Disorders, Colonoscopy Prof Paul Miskovitz (Ed), ISBN: 978-953-307-568-6, InTech. http://www.intechopen.com/ books/colonoscopy/autofluorescence-imaging-for-diagnosing-intestinal-diso rders.
56. Sanduleanu S, Driessen A, Gomez-Garcia E, Hameeteman W, de Bruine A, Masclee A. In vivo diagnosis and classification of colorectal neoplasia by chromoendoscopy-guided confocal laser endomicroscopy. Clin Gastroenterol Hepatol. Apr 2010;8(4):371-378.
57. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. Mar 2007;132(3):874-882.